Fig. 1From: Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinibBCR-ABL1 levels over time. IS, International Scale; MMR, major molecular response (BCR-ABL1 ≤ 0.1% on the IS). * BCR-ABL1 = 0.00% on the ISBack to article page